[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Julka PK, Puri T, Rath GK: A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int; 2006 Feb;5(1):110-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
  • BACKGROUND: Patients with carcinoma of the gallbladder have advanced, unresectable tumor at the time of presentation and face a dismal prognosis in the absence of a standard palliative chemotherapy regimen.
  • This study was undertaken to evaluate the efficacy and safety of combined chemotherapy of gemcitabine and carboplatin in 20 patients with advanced gallbladder carcinoma.
  • METHODS: The criteria of eligibility included chemonaive patients with unresectable gallbladder cancer, bidimensionally measurable disease, Zubrod's performance status < or = 2, and adequate major organ function.
  • RESULTS: In this group of 20 patients with advanced gallbladder carcinoma 6 were men and 14 women, with a median age of 55 years.
  • The stage of the tumor at presentation was IVB in 14 patients (70%), IVA in 3 (15%) and III in 3 (15%).
  • The median time to progression of the tumor was 33.8 weeks, and 1-year survival rate of the patients was 43.3%.
  • Anemia of WHO grade III or IV was seen in 2 patients (10%) and 1 patient (5%), respectively.
  • CONCLUSION: With mild toxicity, combined chemotherapy of gemcitabine and carboplatin is effective in the treatment of advanced gallbladder carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481295.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


2. Wang ML, Foo KF: Adjuvant chemoradiotherapy for high-risk pancreatic cancer. Singapore Med J; 2009 Jan;50(1):43-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
  • INTRODUCTION: The role of adjuvant chemoradiotherapy for resected pancreatic cancer remains controversial.
  • This is a single institutional review, evaluating the outcomes of patients with high-risk resected pancreatic cancer and treated with adjuvant chemoradiotherapy.
  • METHODS: A retrospective review was conducted on 18 consecutive patients with pancreatic cancer and treated with adjuvant chemoradiotherapy at the Department of Radiation Oncology, National Cancer Centre, Singapore, between January 2000 and December 2004.
  • Patients had either AJCC 2002 Stage I (17 percent), Stage II (11 percent), Stage III (22 percent) or Stage IVA (50 percent).
  • Concurrent chemotherapy was administered with 5-fluorouracil (56 percent), gemcitabine (28 percent) or capacetabine (17 percent).
  • RESULTS: The median follow-up of patients still alive at the time of analysis was 48 months.
  • Metastatic disease had developed in 13 patients.
  • CONCLUSION: The data supports the use of adjuvant chemoradiotherapy for high-risk pancreatic cancer.
  • Although radiotherapy is effective in reducing local failure, effective systemic treatment is also essential.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224083.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Sano K, Takayama T, Murakami K, Saiki I, Makuuchi M: Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma. Clin Cancer Res; 2003 Sep 1;9(10 Pt 1):3679-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma.
  • PURPOSE: Retinoid analogues have been reported to inhibit the growth of hepatocellular carcinoma (HCC).
  • In this study, we investigated the expression of RAR mRNAs and proteins in resected HCC and nontumor liver tissue.
  • EXPERIMENTAL DESIGN: Reverse transcription-PCR and Western blot analysis were applied to investigate the expression of RAR mRNAs and proteins in 32 resected samples of HCC and 14 samples of nontumor liver tissue.
  • RESULTS: The intensities of mRNA and protein for RAR-alpha in HCC tissue were significantly higher than those in nontumor liver tissue (P = 0.002 and P = 0.002, respectively).
  • There was only one significant correlation between the higher intensity of RAR-beta protein and tumor stage (stage I/II versus stage III/IVA, P = 0.01) among clinicopathological variables in the HCC patients.
  • However, in vitro experiments showed that the growth of a RAR-alpha-elevated HCC cell line was potently inhibited by treatment with retinoids at concentrations that did not affect the growth of primary-cultured hepatocytes.
  • CONCLUSIONS: These results imply that RAR-alpha is the dominant receptor in HCC, which suggests that RAR-alpha-selective retinoid analogues may be useful for chemotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Receptors, Retinoic Acid / biosynthesis
  • [MeSH-minor] Blotting, Western. Cell Division. Cell Line, Tumor. Cell Nucleus / metabolism. Dose-Response Relationship, Drug. Humans. Liver / metabolism. Neoplasms / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14506158.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 0 / retinoic acid receptor gamma
  •  go-up   go-down


Advertisement
4. Udaka T, Konishi Y, Waki N, Hayama M, Kubo M, Sogabe O, Maeda H, Mizuta M, Shirakawa K: [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer]. Gan To Kagaku Ryoho; 2008 Jun;35(6):937-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer].
  • The feasibility and anti-tumor activity of gemcitabine (GEM) as postoperative adjuvant chemotherapy were evaluated retrospectively.
  • Between September 1998 and June 2007, patients with resected invasive pancreatic cancer (stage III, IVa, IVb) were given adjuvant chemotherapy with GEM (GEM group, n=10) or did not receive chemotherapy (n=11).
  • There was a significant difference in overall survival between the GEM group and the no-chemotherapy group (p=0.037), but there was no significant difference in disease-free survival between the two groups.
  • Adjuvant chemotherapy with GEM was feasible and showed a benefit in patients with invasive pancreatic cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633220.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Yamamitsu S, Kimura H, Yamada Y, Inui N, Hiyama S, Hirata K, Kimura Y, Shirasada T: [Long-term repeatable chemotherapy for patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2006 Jun;33 Suppl 1:213-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].
  • At present, the advanced pancreatic cancer is known to be one of the most resistant malignancies on chemotherapy.
  • To improve the efficacy of chemotherapy, we shifted the aim of chemotherapy from a tumor regression to long-term survival, and sought for a repeatable regimen with little toxicity.
  • Some of the novel (repeatable) regimens used a combination of 5-FU/S-1, CDDP and paclitaxel performed for 10 patients with advanced pancreatic cancer (4 cases of Stage IVa and 6 cases of Stage IVb).
  • All of non-hematological adverse reactions were observed under grade 2 and did not disrupt the maintenance of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Quality of Life. Remission Induction. Survival Rate. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898005.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Yamamitsu S, Kimura H, Yamada Y, Inui N, Hiyama S, Hirata K, Kimura Y, Koito K, Shirasaka T: [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1059-66
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer].
  • The remedy, especially chemotherapy, for advanced pancreatic cancer is hardly ever successful in terms of efficacy rate and survival period, because it is virtually unable to contribute to the improvement of median survival time (MST).
  • Thus,we devised a new intermittent dosage regimen utilizing the cell cycle difference of normal GI tract, bone marrow cell and pancreatic cancer cell, making use of 5-FU (-->S-1), CDDP and paclitaxel in March 2002.
  • Ten patients with advanced pancreatic cancer (4 in Stage IVa and 6 in Stage IVb) were treated with this new regimen.
  • Although adverse effects related to this regimen were clinically manageable, it was difficult to improve MST of patients with advanced pancreatic cancer with chemotherapy alone including this regimen.
  • Hence, we devised another regimen with the joint use of radiotherapy along with the same chemotherapy regimen in January 2003.
  • Twenty patients with advanced pancreatic cancer (Stage IV) were treated with this regimen.
  • It is presently under way, and an efficacy ratio of 35.0%, 1-year survival ratio of 86.3% and 2-year survival ratio of 64.0% were obtained by May 2005, showing that this may contribute to the extension of survival time of Stage IV pancreatic cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Anorexia / chemically induced. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Nausea / chemically induced. Paclitaxel / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637542.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Fujino Y, Ueda T, Kamigaki T, Takase S, Ajiki T, Kamoda Y, Matsumoto I, Yasuda T, Kuroda Y: Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Pancreas; 2007 Apr;34(3):335-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
  • OBJECTIVES: The prognosis of patients with advanced pancreatic cancer remains very poor.
  • This study was designed to elucidate the prognostic factors of patients with pancreatic cancer to evaluate appropriate treatment with gemcitabine.
  • METHODS: Ninety-nine consecutive patients with stage IV pancreatic cancer were treated in the gemcitabine era at the Kobe University Hospital.
  • Prognostic variables for survival were analyzed (sex, age, performance status, main site of the tumor, tumor size, major vessel invasion, distal metastasis, resection, gemcitabine, radiation, and pathological factors).
  • The Cox proportional hazards model was used to determine the factors influencing the survival of patients with stage IV pancreatic cancer.
  • RESULTS: Multivariate analysis revealed that pancreatic resection, gemcitabine, and distant metastasis significantly influenced the survival of all patients with stage IV pancreatic cancer.
  • Pancreatic resection and gemcitabine were significant factors influencing the survival of patients with stage IVa pancreatic cancer, whereas gemcitabine was the strongest factor influencing stage IVb pancreatic cancer.
  • CONCLUSIONS: Gemcitabine has a possible role for stage IV pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414056.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Wato M, Inaba T, Ishikawa H, Ishikawa S, Baba N, Miyoshi M, Senoh T, Nagano T, Takaguchi K, Watanabe S, Kawai K: [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer]. Nihon Shokakibyo Gakkai Zasshi; 2010 Oct;107(10):1676-85
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
  • A 63-year-old man with Stage IVa pancreas tail cancer was admitted for a distal pancreatectomy and splenectomy; adjuvant chemotherapy with gemcitabine was also administered.
  • The chemotherapy was terminated after 16 courses due to hemolytic anemia, thrombocytopenia and renal dysfunction.
  • Physicians should be cautious of hemolytic uremic syndrome as a possible adverse reaction to gemcitabine and be aware that tests are needed for its early detection.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Hemolytic-Uremic Syndrome / chemically induced. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / adverse effects. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hemolytic uremic syndrome.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938119.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A: Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol; 2008 Feb;31(1):71-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
  • OBJECTIVE: Our aim was to examine the efficacy and tolerability of intra-arterial infusion chemotherapy with 5-fluorouracil (5-FU) and cisplatin in advanced pancreatic cancer.
  • METHODS: Sixteen patients with unresectable locally advanced or metastatic pancreatic cancer (12 Stage IVa and 4 Stage IVb with liver metastasis) were enrolled.
  • The catheter for intra-arterial infusion was placed at the position to distribute chemotherapeutic drugs to both the pancreatic tumor and the liver.
  • RESULTS: In 12 Stage IVa locally advanced patients, the response rate was 58.3% (7 partial response).
  • The median survival time was 22.0 months, and the 1-, 2-, and 3-year survival rates were 83.3%, 41.7%, and 16.7%, respectively.
  • The locally advanced patients treated with intra-arterial infusion chemotherapy showed significantly better survival than the control patients.
  • In contrast, Stage IVb patients with liver metastasis showed no response to the treatment (response rate, 0%).
  • Treatment was discontinued in 2 patients until recovery from hematologic or hepatic toxicity, but fatal adverse events were not observed.
  • CONCLUSION: These results suggest that intra-arterial infusion chemotherapy with 5-FU and cisplatin is tolerable and feasible treatment to improve the prognosis in locally advanced pancreatic cancer patients without distant metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Maximum Tolerated Dose. Middle Aged. Pancreaticoduodenectomy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376231.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Ohta H, Shioji K, Maruyama Y, Watanabe K, Aiba T, Baba Y, Seki K, Yanagi M, Iiri T, Ishizuka K, Isokawa O, Nakamura A, Natsui M, Furukawa K, Suzuki Y, Ban-Nai H, Motoyama N, Mori S, Aoyagi Y: [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2357-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
  • We performed a retrospective survey at 15 hospitals in Niigata Prefecture to assess the effectiveness of gemcitabine in patients with stage IV pancreatic cancer and to analyze prognostic factors impacting survival in patients with stage IVb.
  • The subjects were 244 unresectable or metastatic pancreatic cancer patients(IVa 68, IVb 176)who were treated with gemcitabine as first-line therapy.
  • The overall response rate was 6.1% and the median survival time(MST)was 194 days.
  • The MST of stage IVa(312 days)was double that of stage IVb(167 days).
  • Prognostic factors for survival of patients with stage IVb were analyzed(performance status, response rate, liver metastasis, peritonitis carcinomatosa, paraaortic lymph node metastasis)with the Cox proportional hazards model.
  • When we compare an effect of other chemotherapy with GEM, we should treat stage IVa and stage IVb separately, and subdivision is necessary for stage IVb.
  • [MeSH-major] Data Collection / statistics & numerical data. Deoxycytidine / analogs & derivatives. Hospitals / statistics & numerical data. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Sato I, Ueda N, Kinoshita E, Minato H, Ohno K, Nakaya N, Shimasaki T, Nakajima H, Kosaka T, Motoo Y: [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1341-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
  • A 73-year-old man diagnosed as having pancreatic body cancer with multiple liver metastases was referred to our hospital.
  • The initial dose of S-1 was 80 mg, and gradually increased to 150 mg/day.
  • The liver metastases disappeared and the pancreatic tumor was markedly reduced in size at the completion of 4 courses.
  • Distal pancreatectomy was carried out at 7 months since his first visit.
  • Pathological diagnosis was non-functioning well-differentiated neuroendocrine carcinoma (pT4, pN0, pM0, Stage IVa).
  • S-1 might be a candidate for chemotherapy for this neuroendocrine tumor.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Liver Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy. Neuroendocrine Tumors / pathology. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647723.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Reni M, Cordio S, Passardi A, Panucci MG, Passoni P, Oliani C, Luppi G, Galli L, Nicoletti R, Villa E: Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA). J Clin Oncol; 2004 Jul 15;22(14_suppl):4010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA).
  • : 4010 Background: Single agent G is the standard therapy in advanced PA, yielding 10% objective responses (OR) and 20% 1-yr overall survival (OS).
  • Due to the potential impact of salvage therapy on OS, the primary endpoint of the study was PD free survival (PFS).
  • PFS and OS were analyzed on an intent-to-treat basis Results: Between April 2000 and April 2003, 104 pts, stratified by center and stage, were enrolled: 5 pts were ineligible due to liver function (2 in each arm) and biliary tract cancer (1 arm B), 52 pts were allocated to arm A and 47 to arm B.
  • Two arm A pts did not receive PEFG due to death before treatment start or delivery of G alone.
  • Salvage therapy was given to 54% of arm B pts and 41% of arm A pts.
  • Time to 2<sup>nd</sup> PD was longer in arm B (p=.05) Conclusions: PEFG yielded a significantly better outcome than standard G.
  • This is the 1<sup>st</sup> time that a combination chemotherapy has resulted superior to a single agent in advanced PA No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Shinchi H, Takao S, Maemura K, Noma H, Kitazono M, Ueno S, Sakoda M, Kubo F, Aikou T: [A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1653-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer].
  • Abdominal CT revealed an avascular tumor at the uncinate process of the pancreas measuring 36x30 mm.
  • During laparotomy,the tumor was deemed unresectable (T4NXM0, Stage IVa),and duodenojejunostomy was performed.
  • External-beam radiotherapy (EBRT) (50.4 Gy/28Fr) with concurrent twice-weekly gemcitabine (GEM) (40 mg/m(2)/day) was delivered.
  • The patient received 13 cycles of GEM chemotherapy until the appearance of a grade 2 facial rash.
  • Gemcitabine-based chemo-radiation seems to be a safe and effective regimen for unresectable pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Quality of Life. Radiotherapy Dosage. Survivors. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; FP protocol
  •  go-up   go-down


15. Iwauchi T, Amano R, Ohira G, Nakamoto K, Doi Y, Yamada N, Ohira M, Hirakawa K: [A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2373-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].
  • We report a case of postoperative liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine (GEM) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP).
  • A 70s woman was referred to our hospital for treatment of a pancreatic head cancer in November 2007.
  • Pancreaticoduodenectomy with a regional lymphadectomy was performed in December 2007 and the pathological stage was Stage IVa.
  • Adjuvant chemotherapy of UFT was administered one month after operation.
  • However, a second chemotherapy of S-1 was administered because DUPAN-2 levels showed a high range 8 months after operation.
  • Ten months after operation, abdominal computed tomography demonstrated a 2 cm tumor in the liver.
  • Then, hepatic arterial infusion (HAI) chemotherapy of 5-FU/CDDP was instituted weekly.
  • We suggest that HAI chemotherapy of 5-FU+CDDP might be an effective treatment to liver metastasis of pancreatic cancer and prolong prognosis of those patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Drug Resistance, Neoplasm. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Lymph Node Excision. Oxonic Acid / administration & dosage. Pancreaticoduodenectomy. Tegafur / administration & dosage


16. Hisama S, Kimura M, Nishimura T, Matsushita H, Okamura S, Saitoh S, Shimokawa Y, Arakawa A, Toyama H, Tanaka Y: [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1337-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
  • A 65-year-old man suffering from acute pancreatitis underwent MRI scanning, which revealed a low signal on the T1 and T2 sequences, and hypovascularity in arterial phase in the head of the pancreas.
  • FDG-PET was highly suggestive of pancreatic cancer (T4N1M0, Stage IVa) with lymph node metastasis.
  • He was treated with systemic chemotherapy using gemcitabine (GEM) followed by radiotherapy.
  • His symptoms gradually improved with a reduction in size of the primary lesion.
  • The patient has been receiving systemic chemotherapy using S-1 without recurrence.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Remission Induction. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647722.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Hara T, Nagata M, Yamashita Y, Fujimoto K, Muraki Y, Yasuda Y, Kurahashi T: [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1233-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
  • Combination chemotherapy with S-1 and gemcitabine(GEM)was given to patients with advanced pancreatic cancer and favorable results were obtained.
  • These patients were 77-(Stage IVa), 68-(Stage IVb), and 64-year-old males (Stage IVb).
  • One course consisted of a 2-week treatment period and a recovery period; this course was repeated in all of these patients.
  • The 3 types of patients have survived for a year and five months, a year and three months, and nine months, respectively, after diagnosis.
  • In the first patient, who was in Stage IVa, the primary cancer has been maintained in a reduced state without metastasis.
  • In the other two patients, who were in Stage IVb, the primary cancer and hepatic metastatic lesions have been reduced remarkably.
  • Combination therapy with S-1 and GEM can be provided for a long-term treatment with few adverse reactions on an outpatient basis.
  • Based on the changes in tumor markers, we observed that the inhibitory effects of this combination chemotherapy are immediate and persistent with long-term treatment.
  • Therefore, we expect S-1/GEM combination therapy to be the chemotherapy of choice for advanced pancreatic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633271.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Satoh E, Maruyama M, Koike T, Shima Y, Ohinata R, Koide A, Sanada T, Maruyama S, Ebuchi M, Sakoma T: [A case report of intra-operative radiotherapy and gemcitabine for unresectable pancreatic body cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2115-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of intra-operative radiotherapy and gemcitabine for unresectable pancreatic body cancer].
  • We report an effective case of fifty-seven year-old female with unresectable pancreatic cancer.
  • Its chief complaint of the case was epigastralgia in April 2007, and the diagnosis was locally-advanced cancer of pancreatic body (4 cm, Stage IVa) in June 2007.
  • Laparotomy was performed, but the locally-advanced cancer was unresectable because of the invasion to the celiac trunk and superior mesenteric artery.
  • Tumor biopsy and intra-operative radiotherapy (IORT, 12 MeV, 20 Gy) were only performed.
  • After laparoptomy, systemic chemotherapy (gemcitabine 1,000 mg/body) was performed once a week.
  • After 4-set chemotherapy, her cancer pain was completely relieved and the tumor size was decreased to 25 mm on CT scan in October 2007.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106541.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


19. Takada J, Okuda K, Kenno S, Shimada S, Oba G, Shimokuni T, Aoki T, Hamada H: [S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2120-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
  • OBJECTIVE: Treatment results of pancreatic head carcinoma are not good and long-term survival, especially in nonresectable cases is extremely difficult to obtain.
  • The case reported here is of nonresectable pancreatic head carcinoma in which S-1+gemcitabine (GEM) proved to be effective.
  • Jaundice was also noted and upon further study, pancreatic head carcinoma, portal vein and common hepatic artery infiltration along with duodenal infiltration were diagnosed.
  • Gastrojejunostomy and cholecystectomy were performed with a preoperative diagnosis of Phb, TS2 infiltrative type T4, CH (+), DU (+), S (+), RP (-), PV (+), Ach (+), PLX, OO (-), N0, M0, and Stage IVa.
  • At 1 year and 5 months from the initial diagnosis, there has been no recurrence and chemotherapy is being continued.
  • In the case reported here, there have been no adverse side-effects from the S-1+GEM therapy, it is a safe method which does not lower QOL in patients with unresectable pancreatic carcinoma, and we can look forward to the possibility of extended survival times.
  • CONCLUSION: In the case of unresectable pancreatic carcinoma, S-1+GEM therapy may be able to provide an improved long-term prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Angiography. Biomarkers, Tumor / blood. Drug Combinations. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / radiography. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106543.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Kouloulias VE, Nikita KS, Kouvaris JR, Uzunoglu NK, Golematis VC, Papavasiliou CG, Vlahos LJ: Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy. J Hepatobiliary Pancreat Surg; 2001;8(6):564-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy.
  • BACKGROUND/PURPOSE: The aim of our study was to evaluate the feasibility and the efficacy of cytoreductive surgery (CS) with intraoperative chemo-hyperthermia in the management of advanced stage IVA (T4N0M0) pancreatic cancer.
  • METHODS: From August 1995 through March 1996, seven patients with unresectable adenocarcinoma of the pancreas underwent CS, with preoperative chemotherapy (5-fluorouracil [FU] for 96 h), plus 45-Gy external beam postoperative irradiation with a 6-MeV linear accelerator (1.8 Gy per fraction, 5 days per week).
  • A single session of intraoperative hyperthermia was performed with a waveguide-type applicator operating at 433 MHz, and temperature was measured by inserting a flexiguide needle catheter carrying a thermometry probe with three measuring points into the tumor.
  • The tumor region was heated to 43 degrees C-45 degrees C for up to 60 min, while 5-FU 500 mg was injected simultaneously through the gastroduodenal artery into the splenic artery (intraoperative regional chemotherapy).
  • After the combined treatment, there was a significant decrease in the values of both serum carcinoembryonic antigen (CEA; P = 0.017, Wilcoxon test) and carbohydrate antigen (CA)19-9 ( P = 0.016; Wilcoxon test), from 7.6 +/- 1.5 ng/ml CEA and 869.6 +/- 126.9 U/ml CA to 3.5 +/- 0.8 ng/ml CEA and 104.7 +/- 35.4 U/ml CA19-9.
  • The median overall survival was 18.5 (SE, 1.8) months.
  • CONCLUSIONS: Our preliminary clinical results suggest the tolerability and the considerable potential advantage of using cytoreductive resection with preoperative chemotherapy, intraoperative chemo-hyperthermia, and external beam postoperative radiotherapy for the management of advanced adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / therapy. Hyperthermia, Induced. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Feasibility Studies. Female. Fluorouracil / therapeutic use. Humans. Intraoperative Period. Male. Middle Aged. Radiotherapy, High-Energy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11956909.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Yamashita S, Sakon M, Hiura Y, Nakano K, Higaki N, Murakami M, Hayashida H, Kan K, Ichihara T: [A case of metastases of umbilicus (Sister Mary Joseph's nodule)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2112-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of advanced unresectable pancreatic cancer (cT4N1M0/stage IVa).
  • Chemo-radiation therapy (CRT) with GEM (1,000 mg/body) was administered once a week on days 1, 8 and 15 for 3 weeks.
  • The radiotherapy dose was 45 Gy (1.5 Gy x 2/day, 15 days).
  • After CRT, the patient was treated with a GEM+ UFT-E combination chemotherapy.
  • Microwave Coagulation Therapy for the liver metastasis and tumorectomy for metastasis of umbilicus were performed.
  • But he died after 4 months from the therapies.
  • [MeSH-major] Abdominal Neoplasms / secondary. Pancreatic Neoplasms / pathology. Umbilicus / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Tomography, X-Ray Computed. Treatment Failure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106540.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DU-PAN-2 antigen, human
  •  go-up   go-down


22. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg; 2003 May;185(5):476-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
  • BACKGROUND: Patients with cancer who undergo pancreaticoduodenectomy (PD) followed by radiation and 5-fluorouracil (5-FU) therapy have experienced median overall survival from 18 to 24 months and an actuarial 2-year overall survival from 34% to 48%.
  • METHODS: From July 1995 to May 2002, 43 patients with adenocarcinomas in the pancreatic head underwent PD at our institution.
  • Final pathologic findings were stage I (2%), II (12%), III (72%), and IVa (14%) while 84% had positive lymph nodes (average number of nodes positive was 3.2 nodes, (range 0 to 13).
  • These patients then received our investigational protocol consisting of external-beam irradiation at a dose of 4,500 to 5,400 cGy (25 fractions over 5 weeks) and three-drug chemotherapy: continuous infusion 5-FU (200 mg/m(2) daily, days 1 to 35), weekly intravenous bolus cisplatin (30 mg/m(2) daily, days 1,8,15,22,29), and subcutaneous alpha, interferon (3 x 10(6) units, days 1 to 35).
  • RESULTS: All patients completed radiation therapy.
  • With a mean follow-up time of 31.9 months, 67% of the patients are alive.
  • CONCLUSIONS: This follow-up report further suggests overall survival may be improved for patients with adenocarcinoma in the pancreatic head using an adjuvant interferon-based chemoradiation protocol.
  • These results are obtained despite a high incidence of node involvement and advanced tumor stage.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-alpha / administration & dosage. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12727570.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Doi R, Kami K, Ito D, Kawaguchi Y, Uemoto S, Yoshida S: [Surgical treatment of carcinoma of the pancreas]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):168-72
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of carcinoma of the pancreas].
  • Invasive ductal carcinoma of the pancreas (pancreatic cancer) is mainly treated by operative resection, radio-chemotherapy, or chemotherapy.
  • The survival rate of the patients with each treatment is not good when compared with that in other cancers.
  • Meanwhile, it is still true that surgical resection remains the only method offering pancreatic cancer patients long-term survival or cure.
  • In addition, the volume of pancreatic cancer patients treated at the institution and the surgeon's personal experience may greatly affect the decision.
  • A recent randomized clinical trial from Japan revealed that surgical resection has a survival advantage over chemo-radiation therapy for locally advanced pancreatic cancer, which is defined as stage IVa in the fourth Japanese edition of the Classification of Pancreatic Carcinoma.
  • Moreover, guidelines for clinical practice for pancreatic cancer by the Japan Pancreas Society have been issued very recently.
  • In addition, the surgical indications should be reevaluated in combination with the adjuvant or neoadjuvant chemotherapy in future.
  • [MeSH-major] Carcinoma, Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878408.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


24. Sunamura M, Kobari M, Shibuya K, Takeda K, Matsuno S: [The role of preoperative staging for pancreatic cancer]. Nihon Geka Gakkai Zasshi; 2000 Feb;101(2):212-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of preoperative staging for pancreatic cancer].
  • Despite the poor prognosis of pancreatic carcinoma patients, surgical resection remains the only potentially curative treatment.
  • According to the report of a national survey of pancreatic cancer in 1997, patients with S0 or S1, RP0 or RP1, and N0 or N1 disease have longer survival periods compared with patients with S2, RP2, and N2 disease.
  • Therefore patients classified as Stage I, Stage II, or Stage III are recognized as candidates for surgical resection.
  • Patients classified as Stage IVb because of positive P factor or positive H factor are selected for conservative treatment such as chemotherapy and irradiation.
  • It remains to be clarified whether patients classified as Stage IVa should undergo surgical resection or not.
  • Future prospective randomized studies of patients with Stage IVa disease will reveal whether surgical resection or chemoradiation is effective.
  • Helical CT is useful to evaluate S and RP factors for definitive preoperative staging.
  • [MeSH-major] Neoplasm Staging / methods. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10734639.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


25. Satoh E, Maruyama M, Koide A, Maruyama S, Ebuchi M, Sakoma T: [A case report of intraabdominal bleeding in unresectable pancreatic cancer after intraoperative radiotherapy]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2005-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of intraabdominal bleeding in unresectable pancreatic cancer after intraoperative radiotherapy].
  • We report a death case of 56-year-old male with unresectable pancreatic cancer.
  • Its diagnosis was locally-advanced cancer of pancreatic head (Stage IVa) in February 2006.
  • However, he desired no medical treatment until obstructive jaundice (T-Bil 25 mg/dL) appeared.
  • In November 2006, systemic chemotherapy (S-1 +gemcitabine) was performed.
  • After the chemotherapy, vomiting had appeared because of duodenal stenosis.
  • The autopsy demonstrated the rupture of splenic pseuoaneurysm due to necrotizing pancreatitis of pancreatic tail, and cancer of pancreatic head was almost viable and IORT was not effective.
  • [MeSH-major] Abdominal Cavity / pathology. Hemorrhage / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Autopsy. Humans. Male. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219880.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM: Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest; 2004;22(4):505-14
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
  • PURPOSE: To assess the efficacy and toxicity of combination therapy with gemcitabine and docetaxel in patients with unresectable pancreatic carcinoma.
  • PATIENTS AND METHODS: Thirty-four patients with unresectable stage III, IVA, and IVB pancreatic carcinoma were eligible for this study.
  • Due to a high incidence of myelosuppression in this first group, the treatment schedule was modified in the remaining patients to gemcitabine 1,000 mg/m2 i.v. and docetaxel 40 mg/m2 i.v. on days 1 and 8 of a 21-day schedule.
  • Partial responses noted in the pancreas and a variety of metastatic sites were maintained for 4 to 12 months (median 6 months).
  • The median time to progression was 6 months, and median survival was 10.5 months.
  • CONCLUSION: The response and survival data reported here for combination therapy with gemcitabine and docetaxel are encouraging given the poor prognosis associated with unresectable pancreatic cancer.
  • These data suggest that gemcitabine plus docetaxel may be more effective than either agent alone in the treatment of pancreatic cancer and warrants further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neutropenia / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565807.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


27. Ohta K, Sawamura A, Miyahara E, Kim R, Toge T: [A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)]. Gan To Kagaku Ryoho; 2001 Apr;28(4):516-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of inoperable advanced gall bladder cancer responding to intra-arterial infusion of 5-fluorouracil (5-FU) and leucovorin (LV)].
  • The prognosis in cases of inoperable advanced gall bladder cancer is poor.
  • We report here a case of inoperable advanced gall bladder cancer that responded to treatment with continuous intra-arterial infusion of 5-FU and bolus injection of LV for biochemical modulation.
  • A mass lesion which occupied from the dorsal surface of the liver to the pancreatic head was found by ultrasonography, and she was referred to our hospital for further diagnosis and therapy.
  • The diagnosis was advanced gall bladder cancer of Stage IVa (S2, N3, P0, H0, Hinf1, Dinf1).
  • For the selective arterial infusion of anticancer drugs, the patient underwent intra-arterial cannulation into the common hepatic artery, with a connecting subcutaneous port for arterial infusion therapy.
  • The treatment schedule for 5-FU and LV therapy consisted of continuous infusion of 5-FU of 333 mg/m2 for 72 hr and bolus injection of LV of 20 mg/m2 3 times at 24 hr intervals.
  • This treatment was repeated every 2 weeks.
  • No side effects were observed after the first administration during hospitalization, so the treatment was continued up to 17 times on an outpatient basis.
  • These findings may imply that treatment with intra-arterial infusion of 5-FU and LV can be an effective chemotherapy for prolongation of survival in patients with inoperable advanced gall bladder cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Gall Bladder Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329787.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Takahashi S, Homma H, Akiyama T, Mesawa S, Koike K, Kogawa K, Hirata K, Niitsus Y: [Evaluation of the endoprosthesis by metallic stent and tube stent for malignant biliary stenosis]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1630-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group A consisted of 6 patients of cholangiocarcinoma who underwent hepatic arterial infusion chemotherapy associated with radiotherapy.
  • Groups B and C consisted of 8 and 6 patients of stage IVa and IVb pancreatic carcinoma, respectively, who underwent hepatic and splenic arterial infusion chemotherapy following transcatheter peripancreatic arterial embolization.
  • The 50% patent time was 12 months, 6 months and 7 months in groups A, B and C and the 50% overall survival time was 16 months, 23 months and 13 months, respectively.
  • This technique appears to offer significant benefit in selecting patients with this type of biliary obstruction.
  • [MeSH-major] Cholangiocarcinoma / complications. Cholestasis / therapy. Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prosthesis Design. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315891.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Kishiwada M, Kawarada Y, Taoka H, Isaji S: Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy. Hepatogastroenterology; 2002 Nov-Dec;49(48):1704-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy.
  • BACKGROUND/AIMS: Pancreatic cancer remains a challenging disease with a dismal prognosis.
  • METHODOLOGY: Fifty-five patients admitted to our Department between April 1993 and April 2000 for resection of pancreatic cancer were the subjects of this study.
  • RESULTS: According to the TNM staging system (UICC), 9 (56%) in the 16 patients who underwent staging laparoscopy were found to have Stage IVb disease, 4 (25%) to have Stage IVa disease and only 3 (19%) to have Stage III disease.
  • The three patients with small liver metastases received 2-ICA therapy.
  • CONCLUSIONS: Staging laparoscopy is useful for correctly diagnosing tumor stage in pancreatic cancer patients and selecting appropriate treatment.
  • The 2-ICA therapy is a new and effective method of treatment for advanced cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorouracil / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Laparoscopy. Leucovorin / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397771.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement